ZENOTECH LABORATORIES LIMITED
ANNUAL REPORT 2006-2007
CHAIRMAN'S REPORT
Dear Shareholders
Over the last four years, your company's research and development team has
developed technology platforms in generic biologicals, monoclonal
antibodies and speciality injeetables like oncology. As a result, your
company has one of the most robust product pipelines in the speciality /
generic biologics space.
Your company has licensed its generic C - CSF to Ranbaxy for clinical
development and launch in the EU and later in the US market. Your company
is one of the very few companies that has a fully validated product and a
EU/US FDA approvable biologics manufacturing facilities in India. Your
company has several other such products that will be taken up for clinical
development with partners in the very near future.
In speciality drugs pipeline, your company has developed seven general
injectables for ANDA submissions in the US in collaboration with Ranbaxy.
These seven ANDAs are to be filed in this calendar year. Several other
ANDAs in speciality/oncology area are being taken up for development in the
coming year.
Your company has come a long way since its biologics operations started
four years back. We have robust product pipelines with strong future
potential, US FDA approvable manufacturing facilities and a highly
dedicated and motivated team to take the business forward. However, there
comes a time when the business model can be fully operationalized only with
the help of a strategic partner. Your Board of Directors have chosen
Ranbaxy to be the strategic partner, who brings strong competencies in pre-
clinical and clinical development, global regulatory expertise, strong
intellectual property skills, global marketing reach and above all, a
strong financial wherewithal.
Over the past two years, both the organizations shared a wonderful working
relationship with great chemistry between the teams. The decision to expand
our engagement is a statement of our unified goal to make India a strong
contender in the international biopharmaceuticals market.
Best Wishes,
Dr. Jayaram Chigurupati
Chairman and Managing Director